Disease block
M05-M14 – Entzündliche Polyarthropathien
- Chapter XIII: Krankheiten des Muskel-Skelett-Systems und des Bindegewebes
12Decisions
40Patient groups
Added benefit by patient group
- Considerable3
- Minor2
- Not proven35
Diseases in this disease block
- M05 Seropositive chronische Polyarthritis 5 decisions
- M06 Sonstige chronische Polyarthritis 5 decisions
- M08 Juvenile Arthritis 6 decisions
- M12 Sonstige näher bezeichnete Arthropathien 1 decision
Decisions, newest first
Each decision lists only the patient groups coded with a disease in this disease block.
- 2026-04-16RomvimzaVimseltinibConsiderable
- 2026-03-19TaltzIxekizumabNot proven
- 2025-08-07KevzaraSarilumabNot proven: 2 of 2 patient groups
- 2024-05-02OlumiantBaricitinibNot proven: 2 of 2 patient groups
- 2024-05-02OlumiantBaricitinibNot proven: 2 of 2 patient groups
- 2023-01-05CosentyxSecukinumabNot proven
- 2022-03-03XeljanzTofacitinibNot proven: 4 of 4 patient groups
- 2022-02-17XeljanzTofacitinibNot proven: 6 of 6 patient groups
- 2021-04-15JyselecaFilgotinibMinor: 1 of 6 patient groupsNot proven: 5 of 6 patient groups
- 2020-07-16RinvoqUpadacitinibConsiderable: 1 of 7 patient groupsMinor: 1 of 7 patient groupsNot proven: 5 of 7 patient groups
- 2018-02-15KevzaraSarilumabConsiderable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2017-09-21OlumiantBaricitinibNot proven: 4 of 4 patient groups
Data status: 2026-10-29